This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Ottawa directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
High-throughput kinome-RNAi screen identifies protein kinase R activator (PACT) as a novel genetic modifier of CUG foci integrity in myotonic dystrophy type 1 (DM1).
PloS one · 2021
Separating the Wheat from the Chaff: The Use of Upstream Regulator Analysis to Identify True Differential Expression of Single Genes within Transcriptomic Datasets.
International journal of molecular sciences · 2021
Anisomycin Activates Utrophin Upregulation Through a p38 Signaling Pathway.
Clinical and translational science · 2018
Latest funding
- $30,000
Preclinical assessment of clinic ready compounds for the treatment of Spinal Muscular Atrophy
CIHR · 2013 · Nominated PI
10 publications.
High-throughput kinome-RNAi screen identifies protein kinase R activator (PACT) as a novel genetic modifier of CUG foci integrity in myotonic dystrophy type 1 (DM1).
Neault N, O'Reilly S, Baig AT, Plaza-Diaz J, Azimi M, Farooq F, Baird SD, MacKenzie A
Separating the Wheat from the Chaff: The Use of Upstream Regulator Analysis to Identify True Differential Expression of Single Genes within Transcriptomic Datasets.
Hadwen J, Schock S, Farooq F, MacKenzie A, Plaza-Diaz J
Anisomycin Activates Utrophin Upregulation Through a p38 Signaling Pathway.
Hadwen J, Farooq F, Witherspoon L, Schock S, Mongeon K, MacKenzie A
Sodium Channel Inhibitors Reduce DMPK mRNA and Protein.
Witherspoon L, O'Reilly S, Hadwen J, Tasnim N, MacKenzie A, Farooq F
Current and emerging treatment options for spinal muscular atrophy.
Farooq F, MacKenzie AE
VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models.
Hadwen J, MacKenzie D, Shamim F, Mongeon K, Holcik M, MacKenzie A, Farooq F
Human Growth Hormone Increases SMN Expression and Survival in Severe Spinal Muscular Atrophy Mouse Model.
MacKenzie D, Shamim F, Mongeon K, Trivedi A, MacKenzie A, Farooq F
Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation.
Farooq F, Abadía-Molina F, MacKenzie D, Hadwen J, Shamim F, O'Reilly S, Holcik M, MacKenzie A
Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway.
Farooq F, Molina FA, Hadwen J, MacKenzie D, Witherspoon L, Osmond M, Holcik M, MacKenzie A
p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR.
Farooq F, Balabanian S, Liu X, Holcik M, MacKenzie A
Preclinical assessment of clinic ready compounds for the treatment of Spinal Muscular Atrophy
Principal investigators: Farooq, Faraz T
Keywords: Genetics
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.